Skip to Content

ApoGen Receives $7 Million Investment for Cancer Therapy

Researcher with pipettes and petri dishes

A University of Minnesota startup recently attracted a major investment to support continued development of drug therapies that make cancer treatments more effective.

ApoGen Biotechnologies Inc., launched in October 2014, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells and to move these treatments toward clinical trials. ApoGen is based on discoveries by two U researchers: Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics; and Daniel Harki, Ph.D., assistant professor of medicinal chemistry. John Santini Jr., Ph.D., is the company’s president and CEO.

Cancer therapies often become less effective over time as cancer cells become resistant to treatment. ApoGen’s drugs are designed to block a key enzyme that causes drug resistance, potentially making current and future treatments more effective.

“I have been working with Drs. Harris and Harki to move ApoGen’s science toward clinical and commercial development, and I am thrilled to now partner with Accelerator Corporation,” Santini said in a press release. “We believe that we have assembled the ideal team to advance our therapeutic technologies to slow or stop tumor evolution, which has the potential to yield a significant clinical impact for cancer patients.”

Russ Straate, associate director of the Venture Center, part of the U’s Office for Technology Commercialization, said Accelerator Corporation’s investment marks a milestone for ApoGen.

“For a startup that aims to develop a therapy based on innovative research and bring it to market, an investment like this is crucial,” Straate said. “This funding will help ApoGen in its next steps toward clinical trials and move it closer to the ultimate goal of getting this unique cancer therapy into the hands of those who can benefit from it.”

For more on the Accelerator Corporation’s investment in ApoGen, see the College of Biological Sciences blog.

Kevin Coss

Kevin Coss

Kevin is a writer and public relations associate with the Office of the Vice President for Research.

Latest Blog Posts

Schilling Alaskan Paper Birch tree with white rot

U researchers' work in understanding how different fungi rot trees will help climate modelers predict changes in terrestrial and atmospheric carbon pools.

Read More
Aerial view of farms

New research projects underway within University of Minnesota Extension aim to support the prosperity of rural areas across the state.

Read More
Overhead view of a crowd in a shopping mall

Middle- and working-class workers’ earnings in the US have been stagnating or sinking in recent decades, and researchers believe this trend may stem from the factors in play at the beginning of workers’ careers.

Read More
Scientists in a laboratory

Thirteen projects received over $2.5 million in 2017 Research Infrastructure Awards, which invest in the U's ability to conduct state-of-the-art research.

Read More